The aim of this animal study was to reveal the dose-dependent effects of
melatonin on
aminoglycoside ototoxicity by utilizing distortion product otoacoustic emissions (DPOAEs). Forty-four adult (aged 12 months) rats were divided into five groups. Rats of the control group (group C) were injected with vehicle, while the
melatonin group (group M) received
melatonin (4 mg/kg per day); there were four rats in each of these groups. The study groups consisted of 12 rats per group, and they were treated as follows: 600 mg/kg per day
amikacin (group A),
amikacin plus a low dose (0.4 mg/kg per day)
melatonin (group AML) and
amikacin plus high dose (4 mg/kg per day)
melatonin (group AMH) for 14 days. During the serial measurements on days 0, 5, 10 and 15, the DPOAE results of groups C,M and AML were not significantly changed.
Amikacin ototoxicity findings for input/output (I/O) functions were detected on the 3rd measurement of the study in group A. High-dose
melatonin clearly enhanced and accelerated
amikacin-induced
ototoxicity. The DP-gram amplitudes and I/O amplitudes were reduced, and I/O thresholds were increased in group AMH. Group AMH was the group that was affected the most and earliest by
amikacin. Our study results showed that while low-dose
melatonin protected the inner ear from
ototoxicity, high dose
melatonin facilitated
amikacin-induced
ototoxicity, possibly via the vasodilatory effect, leading to an increased accumulation of
amikacin in the inner ear. Probably, the protective effect of the
melatonin at a dose of 0.4 mg/kg per day is related to its
antioxidant properties. Apparently, the vasodilatory effect of
melatonin seems to be more prominent than its
antioxidant effect in high doses.